After a degree in Microbiology from King’s College London and MPhil from the Horticultural Research International/Univ. of Westminster in the molecular biology of Bacillus thuringiensis and the use of natural gene transfer systems, Jameel then worked in vaccine development for his PhD, where he also gained experience of working with ACDP category 3 pathogens, at the Centre for Applied Microbiology and Research at Porton Down; this was part of the Public Health Laboratory Service, (now the Health Protection Agency).

He had two W.H.O. fellowships in the Immunology Unit, at the Dept. of Medical Parasitology at the London School of Hygiene and Tropical Medicine, continuing his work in vaccinology, applied to the human Schistosoma parasite. He then worked for one year as a Research Assistant at the Ludwig Institute for Cancer Research (UCL-Middlesex branch), working in the lab of Prof. Mike Waterfield on PI3 kinase signalling. During his second period at LSHTM he discovered a new complement regulatory protein receptor in the Schistosoma parasite and went on with funding from the Sir Halley Stewart Trust to characterise this together with Prof. Bob Sim at the MRC Immunochemistry Unit, Univ. of Oxford.

From 2000, he continued for the next five years his research in complement regulation as a Senior Research Fellow, at the University Hospital Basel, Switzerland, in the Dept. of Biomedicine. With funding from the Research Foundations of Roche and Novartis and capital venture funding, his team, with help from Innogenetics NV in Belgium, developed  a synthetic peptide, able to therapeutically inhibit complement-mediated inflammation in vivo.

In 2005 Jameel returned to London, as a Senior Lecturer at London Met. Two years on he was made Professor of Immunology. In late 2007 he started his first experiments on microvesicles, from a preliminary interest in their ability to inhibit complement activation. In January 2009 he founded the Cellular and Molecular Immunology Research Centre, or CMIRC and is now a founding member of the International Society for Extracellular Vesicles, on the editorial panel of the Journal of Extracellular Vesicles, and Scientific Reports and has hosted ‘Microvesiculation and Disease,’ the second such meeting in the UK, in September 2012. Since 2010, Jameel has published 35 papers and one book chapter in this new field.

In December 2017 Jameel moved as the Professor of Biomedical Science to the School of Life and Medical Sciences (LMS) at the University of Hertfordshire to head the Biosciences Research Group. From November 2018 he was Associate Dean for Resesarch in LMS and as of May 2020 has taken the role of Visiting Professor in Biomedical Science. He has supervised 17 PhDs to completion and his main research focus is on Extracellular Vesicles in infectious disease and cancer.

For two decades Prof. Inal has led research at the University of Hertfordshire (UH) and London Metropolitan University (LMU). His work at the Cellular and Molecular Immunology Research Centre (CMIRC), and currently at the Extracellular Vesicle Research (UH) and Cell Communication in Disease Pathology (CDP) (LMU) groups has focused on the role that Extracellular Vesicles (EVs) play in infectious disease and cancer. His group has focused on four main themes:

1. EV-mediated TGF-β1 signalling. This has ranged from TGF-β1-mediated ‘differentiation therapy’ for monocytic leukaemia cells to enhancing invasion in Trypanosoma cruzi and the promotion of epithelial mesenchymal transition (EMT) in cancer cells.
2. The role of EVs in cell adhesion ranging from their capacity to aid the adhesion of Giardia intestinalis to intestinal epithelial cells to the role of outer membrane microvesicles (OMVs) from E. coli and microvesicles (MVs) from Clostridioides difficile in the formation of biofilms and the loss of adhesion proteins in cancer cells during EMT, promoted by TGF-β1-bearing EVs. Through clinical collaboration, the latest project is looking at how to ameliorate vaso-occlusion in Sickle Cell Disorder (SCD) through knowledge of the role EVs play in adhesion of blood cells to the vascular endothelium and if EVs can be used in better monitoring of vaso-occlusive crises.
3. Having been one of the first groups to describe naked enteroviruses (Coxsackievirus B1) using cell membranes (EVs) during invasion of intestinal epithelial cells, the current projects look at Enterovirus 71 and the role of EVs in the capacity of this virus (causing Hand Foot and Mouth Disease) to occasionally cross the blood brain barrier and cause neuropathology, particularly in children.
4. Using EVs as early diagnostic markers in prostate cancer, neurodegenerative disease, SCD and malaria infection.

Collaborations: (i) Oswaldo Cruz Foundation. Curitiba, Brazil; (ii) Haematology @ UCLH/Whittington Hospital; (iii) Exovitaelab, Molecular Biotechnology Centre, Turin, Italy; (iv) School of Biomedical and Allied Health Sciences, College of Health Sciences, University of Ghana